AbbVie (ABBV) Lifts FY26 EPS Guidance; Raises Dividend 5.2%

What happened

AbbVie reported third-quarter results and raised its 2026 adjusted diluted earnings per share guidance to $13.95–$13.99. The board increased the quarterly dividend 5.2% to $1.82 per share, payable February 16, 2027, to holders of record January 15, 2027.

Confirmed

Global impact / market context

Higher guidance suggests AbbVie expects stronger profit, while the bigger dividend signals confidence in cash available to return to shareholders. The guidance includes a $0.69 per-share research charge, which means reported profit may differ from the underlying earnings power investors use to judge the business.

Analyst inference

The article frames this as a mid-cycle confirmation of improving earnings power as AbbVie manages its product portfolio and recent acquisitions. It notes that concrete third-quarter financials versus consensus expectations, plus any 2027 outlook or product updates on the call, would be larger catalysts for the stock.

Analyst inference

What to watch

1. The dividend is $1.82 per share, payable February 16, 2027, to holders of record January 15, 2027, so investors holding the stock on the record date receive that cash payment. Confirmed
2. Watch whether third-quarter revenue and costs versus consensus expectations support the raised 2026 guidance, since the article says those details drive the stock reaction on the earnings call. Analyst inference
3. Watch for any 2027 outlook or product updates on the call, which the article suggests would be a larger catalyst than the guidance and dividend increase alone. Proposed

Evidence

• Original source link unavailable